Hodgkin-limfóma: vizsgálatok itt: Kína
10 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Beijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- Életkor
- 18 év and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - 2. fázisTaking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Chengdu, Guangzhou, Nanchang, Nanjing, Nantong, Shandong, Shanghai, Tianjin, Zhengzhou
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - 1/2. fázisTaking peopleAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Where
- Beijing, Guangzhou, Shanghai
- Életkor
- 12 év and over
- People
- 161 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00 - 1/2. fázisNot yet taking people in KínaPD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma
- Where
- Xuzhou
- Életkor
- 6 év to 18 év
- People
- 112
- Run by
- Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT07641010 - 1. fázisTaking peopleA Phase I Study of JLM019 Injection
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 115
- Run by
- Jecho Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07623850 - 1. fázisTaking peopleAn Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
- Where
- Hangzhou, Xuzhou, Yantai, Zhujiang
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- FBD Biologics Limited
See details and how to joinNCT06487624 - 3. fázisTaking peopleA Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 185
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06170489 - 1. fázisTaking peopleA Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Ruijin Hospital
See details and how to joinNCT06494371 - No phaseTaking peopleThe Pathogenesis and Prognostic Factors of Lymphoma
- Where
- Shanghai
- People
- 2000
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06203652 - 1/2. fázisTaking peopleCD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
- Where
- Beijing
- Életkor
- 16 év to 80 év
- People
- 30
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT02259556